Reimbursement routes and past practices for advanced therapy medicinal products in the Netherlands
We constructed a roadmap of current reimbursement routes for ATMPs in the Netherlands and found that the MA-ATMPs followed a standard reimbursement route similar to non-ATMPs, whereas HE-ATMPs did not.
Authors
- Lourens T. Bloem (ORCID: https://orcid.org/0000-0002-0014-8625)
- Jurriaan Gort
- Renske M.T. ten Ham (ORCID: https://orcid.org/0000-0002-2638-8045)
- Lotty Hooft (ORCID: https://orcid.org/0000-0002-7950-2980)
- Christine C. van Hattem
- Geert Frederix
- Floris Logman
Institutions
- Utrecht University (NL)
- University Medical Center Utrecht (NL)
- Menzis (Netherlands) (NL)
- New York Life Insurance Company (United States) (US)
Publication Details
- Journal
- Regenerative Medicine
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1080/17460751.2025.2594314
- Primary Topic
- Biomedical Ethics and Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00